60562
document
A randomised controlled trial of ranibizumab with and without ketorolac eyedrops for exudative age-related macular degeneration . AIMS To evaluate whether ketorolac eyedrops and ranibizumab intravitreal injections would provide additional benefit over ranibizumab alone in the treatment of choroidal neovascularisation ( CNV ) . METHODS This was a pilot study of eyes with new-onset CNV . A total of 56 patients were enrolled consecutively and randomised in a 1:1 ratio to receive combination treatment with intravitreal ranibizumab and topical ketorolac ( group 1 ) or ranibizumab alone ( group 2 ) . All patients received monthly 0.5-mg ranibizumab intravitreal injections for 3 months , after which monthly injections were administered in accordance with the standard of care . Group 1 patients also self-administered one drop of ketorolac three times a day for 6 months . All patients were followed up for 6 months . RESULTS At 6 months , both groups showed a significant improvement in best-corrected visual acuity ( both , p < 0.001 ) . The two treatments did not show significant differences in terms of the number of ranibizumab injections required . However , the mean 6-month change in central macular thickness ( CMT ) in the combination group was -124 µm ( -29.7 % ; p < 0.001 ) , while in the ranibizumab-only group , the change was -86.9 µm ( -19.5 % ; p=0.001 ) ; thus , the combination treatment resulted in a greater reduction ( p=0.003 ) . The combination treatment had no adverse effects . CONCLUSIONS This pilot study is the first to prospectively investigate the efficacy and safety of a combination of 0.45 % ketorolac eyedrops three times a day and intravitreal ranibizumab injections in patients with CNV , and suggests that topical ketorolac supplements the activity of intravitreal ranibizumab in reducing CMT in CNV .
60563
Intervention_Pharmacological
ranibizumab with and without ketorolac eyedrops
60564
Intervention_Pharmacological
ketorolac eyedrops
60565
Intervention_Pharmacological
ranibizumab intravitreal injections
60566
Intervention_Pharmacological
ranibizumab
60567
Intervention_Pharmacological
intravitreal ranibizumab and topical ketorolac
60568
Intervention_Pharmacological
ranibizumab alone
60569
Intervention_Pharmacological
ranibizumab intravitreal injections
60570
Intervention_Pharmacological
ketorolac
60571
Intervention_Pharmacological
ranibizumab
60572
Intervention_Pharmacological
ketorolac
60573
Intervention_Pharmacological
ranibizumab
60574
Outcome_Physical
exudative age-related macular degeneration .
60575
Outcome_Physical
best-corrected visual acuity
60576
Outcome_Other
number of ranibizumab injections required
60577
Outcome_Physical
6-month change in central macular thickness ( CMT )